Tsc-200-A0201
HPV-Related Endocervical Adenocarcinoma
TScan Therapeutics, Inc.Cell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
7 Active assets in the HPV-Related Endocervical Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
e7 tcr-t cells Christian Hinrichs | Phase 2 | B |
Tsc-202-A0201 TScan Therapeutics, Inc. | Phase 1 | CC |
Tsc-203-A0201 TScan Therapeutics, Inc. | Phase 1 | CC |
Tsc-204-A0201 TScan Therapeutics, Inc. | Phase 1 | CC |
Tsc-204-A0101 TScan Therapeutics, Inc. | Phase 1 | CC |
Tsc-204-C0702 TScan Therapeutics, Inc. | Phase 1 | CC |
Tsc-201-B0702 TScan Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
Tsc-200-A0201 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →